Navigation Links
Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
Date:6/11/2008

Lead Candidate Set for Phase II Clinicals

LA JOLLA, Calif., June 11 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) ("Duska" or the "Company"), announced today that it has been granted an exclusive, worldwide license from Duke University and Johns Hopkins University to develop and commercialize their rights to a portfolio of investigational cardiovascular drugs for the treatment of heart failure. The most advanced drug in the portfolio is expected to enter a Phase II clinical study later this year.

The drug portfolio was developed in part by Jonathan S. Stamler, M.D., George Barth Geller Professor of Research in Cardiovascular Diseases and Professor of Medicine and Biochemistry at Duke University, and Joshua M. Hare, M.D., Louis Lemberg Professor of Medicine, Chief of the Division of Cardiology and Director of the Interdisciplinary Stem Cell Institute at University of Miami. Dr. Hare was formerly associated with Johns Hopkins University.

The Phase II candidate and all other drugs in the portfolio are designed to correct nitric oxide and redox disequilibrium in the failing heart and cardiovascular system. All have a dual mechanism of action of inhibiting the creation of reactive oxygen radicals and concurrently providing nitric oxide in the failing heart. The therapeutic target is the ryanodine receptor, the ion channel in the heart that provides the calcium necessary for the heart to beat. The investigational drugs are believed to improve calcium cycling in the heart by acting on the ryanodine receptor to significantly improve the efficiency of heart contractility.

According to the National Heart, Lung and Blood Institute (NHLBI), there are an estimated five million Americans that suffer from congestive heart failure, a condition characterized by the inability of the heart to efficiently pump blood and by fluid accumulation in the lungs and other tissues. An estimated 300,000 deaths each y
'/>"/>

SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
2. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
3. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
4. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
5. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
8. Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
9. Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
10. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
11. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... Reportlinker.com announces that a ...alogue: ,, Pain Management - Global Trends ...anagement---Global-Trends.html ,, Widespread a...nagement clinics, and the advent of new drugs have...ment market. Healthcare reforms and reimbursement ...
(Date:11/25/2009)...v. 25 ChemoCentryx, Inc., announ... Company,s PROTECT-1 (the Prospective Randomized O...f Traficet-EN(TM) (CCX282-B) in patients with mode...al efficacy with a favorable safety and tolerabili...inical efficacy in the reduction of disease severi...
(Date:11/24/2009)...4 Quest Diagnostics Inco...der of diagnostic testing, information and service...21st Annual Piper Jaffray Healthcare Conference in... Wednesday, December 2, 2009 at 9:30 a.m. Eastern ...l reaffirm its 2009 guidance for revenue growth to...
Breaking Medicine Technology:Reportlinker Adds Pain Management - Global Trends 2Reportlinker Adds Pain Management - Global Trends 3Reportlinker Adds Pain Management - Global Trends 4Reportlinker Adds Pain Management - Global Trends 5Reportlinker Adds Pain Management - Global Trends 6ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2iMedX Announces Acquisition of Worldtech Inc 55211 1iMedX Announces Acquisition of Worldtech Inc 55211 2JNCI news brief 3A Melanosome dynamics and sensitivity of melanoma cells to chemotherapy 55208 1Smokers Cars Loaded With Nicotine 55205 1Smokers Cars Loaded With Nicotine 55205 2Smokers Cars Loaded With Nicotine 55205 3
...l provide a pre-recorded webcast for financial ana... to coincide with the American Pain Society,s,(APS...ata presentations on,investigational tapentadol im...l analgesic, will be presented for the first time ...pentadol researchers, will be,made available concu...
...rial results for NKTR-118 (oral PEG-naloxol) were ...this week at the Annual Meeting of the,American Pa...le-dose Phase,1 study, oral NKTR-118 was shown to ...bsorption and an extended half-life that is up to ...one., NKTR-118 is Nektar,s proprietary peripheral...
Other Medicine Technology:NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 2NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 3NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 4NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 5NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 6
(Date:11/28/2009)...ft spirits, recognize signs of depression , ...ny seniors, the holiday season can trigger melanch...with health issues or worry about money problems, ... To help overcome the seasonal blues, the AGS Foun...vice: , Get out and socialize or invite family a...
(Date:11/27/2009)...tech firm Replikins Ltd. today issued its latest b.... It shows that the lethality of the virus has dr...irus,s current outbreak in the spring of 2009 to r...0.1). The H1N1 infectivity count, however, remains...EB) November 27, 2009 -- Biotech firm Replikins Lt...
(Date:11/27/2009)...Nov. 27 Preventing dise...fortunately every year, new vaccines are being add...cines boost immunity for the same period of time? ...eeded to keep immunity strong? ,, In this mon...can Academy of Pediatrics, Michael Pichichero MD, ...
(Date:11/27/2009)...aCare Holdings has announced that it has become a ...of the largest nonprofit organizations dedicated t... , Delray Beach, FL (Vocus...CBB: XCHO), a company specializing in the marketin...roducts, has announced today that is has become a ...
(Date:11/27/2009)...EATTLE, Nov. 27 Allrecipes.com ,...hanksgiving traffic numbers, with more than 2.8 mi...ing a clear picture of what was served on the bigg...ving meal in 2009 weighed in at 2,225 calories per...ast. According to the Allrecipes site, Sweet Pota...
Breaking Medicine News(10 mins):Health News:Seniors May Need Help Overcoming Holiday Blues 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 4
...hild prodigy marathon runner Budhia Singh, who has...es may be asked to take a dope test, according to ... R S Mishra. Mishra was speaking after he ha...ran such a long distance", he said. He added that ...
...omen lung cancer patients tend to have near normal...ests better in comparison to male lung cancer pati...likely to end with COPD or chronic obstructive pul...al, a publication of the American College of Chest...
...ealth insurance plans show wide variations among d... their premium dollar. // -Employees in the sm... in health insurance premiums than those in the la...nwealth Fund-supported study finds. In this lo...
...erceptin is one of a new generation drug that can ...nd the treatment for patients suffering from later... lots of legal challenges by cancer sufferers to f...hat his local NHS trust would fund for his treatme...
...n the East the health service is losing more than ...ntments. // Despite years of similar complai...ritical. Douglas Pattisson from Hinchingbroo...apacity and extra work.’ Records have shown ...
... recent study has revealed that heart patients who...en times higher a chance of receiving a jolt from ...thm than nonsmokers with the device. // The st...us studies have shown that decreasing or quitting ...
Other Medicine News:Health News:Male Lung Cancer Patients Less Likely To Perform Well in Lung Function Tests 2Health News:Health Insurance Plans Varies among States 2Health News:Health Insurance Plans Varies among States 3Health News:Jolt to Quit Smoking 2
Microforceps: Horizontal Subretinal
Microforceps: Diamond Dusted Pointed
Microforceps: Serrated- Jaws
Microforceps : Asymmetrical Endgripping Forceps
Medicine Products: